Disclaimer

Disclaimer: This communication is for informational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any shares of Intrommune Therapeutics, Inc. (“Intrommune”) or any other securities. Any such offering will be made only in accordance with the terms and conditions of the definitive subscription documents for such offering.

Any investment in Intrommune involves a high degree of risk. Investors should carefully read all of the risk factors attached to the definitive subscription agreement governing their investment. There is no assurance that an investment in Intrommune will be profitable at any time. Only Accredited Investors, as defined in Rule 501(a) promulgated under the Securities Act of 1933, as amended, are eligible to participate in any of the offerings described in the foregoing communication. Additional suitability requirements may apply.

In all cases, potential investors should conduct their own investigation and analysis of any investment in Intrommune and should rely solely on their own judgment, review and analysis in evaluating any investment. While the information contained herein is believed to be accurate and reliable, the information contained herein (including any statements, estimates or financial information provided by Intrommune) has not been independently verified by a third party. Such statements, estimates and financial information reflect various subjective assumptions by management concerning anticipated results, which assumptions are inherently subject to significant uncertainties and contingencies and may or may not prove to be correct. No representation, warranty or undertaking, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by Intrommune, its affiliates or any of their directors, officers, employees, agents, shareholders or advisors as to, or in relation to, the accuracy or completeness of this information, the assumptions and projections incorporated therein, or any other information (whether communicated in written or oral form) transmitted or made available to the recipient, or errors therein or omissions therefrom. Other information contained on or accessed through Intrommune’s website is not a part of this communication.

Neither Intrommune nor its shares of common stock or any other securities will be registered with the Securities and Exchange Commission or the securities regulator of any state. Intrommune’s shares of common stock have not been approved or disapproved, nor has the accuracy or adequacy of this information or any offering materials been endorsed by, the U.S. Securities and Exchange Commission or any state securities commission or regulatory authority, and any representation to the contrary is unlawful.

Forward-Looking Statements: This information contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of Intrommune’s business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as “may,” “should,” “plan,” “intend,” “potential,” “continue,” “believe,” “expect,” “predict,” “anticipate” and “estimate,” the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside Intrommune’s control and involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on Intrommune’s beliefs, assumptions and expectations of future performance, taking into account information currently available to Intrommune. Neither Intrommune nor any other person assumes responsibility for the accuracy or completeness of the forward-looking statements. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. If a change occurs, Intrommune’s business, financial condition, liquidity, results of operations, plans and objectives may vary materially from those expressed in the aforementioned forward-looking statements.

Intrommune toothpaste delivers allergen protein
Toothpaste slurry coats the mouth so more allergen protein can bind with cells on the surface of the oral mucosal epithelium. The opposing charges of the protein and surface cells attracts them to each other to form a strong bond.
Langerhans Cells process and display allergen proteins
Oral Langerhans cells capture allergen protein as it diffuses into the oral mucosa, displaying key identifiers on their surface before travelling to regional lymph nodes.  
Langerhan cells trigger the re-education of the immune system
Once in the regional lymph nodes Langerhans cells activate naive T cells causing them to differentiate into either T regulatory (Treg) cells or T helper type 1 (Th1) cells.
Differentiated T Cells decrease the allergic response
Treg and Th cells travel through lymph vessels and distribute themselves throughout the mucosa of the aerodigestive tract where they decrease the allergic immune response the next time there is exposure to the specific allergen protein. 
Previous
Next